Destiny Pharma PLC teams up with US Department of Veterans Affairs to find ‘new attributes’ for its next-generation antibiotic
NTCD-M3 is remaining created to fight Clostridioides difficile bacterial infections (CDI) in the gut ()
NTCD-M3 is remaining created to fight Clostridioides difficile bacterial infections (CDI) in the gut ()
CEO Neil Clark said: “We have made substantial progress considering that closing the £10.4mln fairness